Interventional Pulmonology — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics — each sourced and dated) with generalizations and synthesized online opinion about culture and "who fits." It's here to help you get curious and go find out for yourself — not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-07-26.

Also called: IP, interventional pulm, "the airway proceduralists." A 1-year fellowship entered after a Pulmonary & Critical Care (or Pulmonary-only) fellowship, rather than a residency you match into from medical school or even a fellowship you reach straight out of IM. Organ systems: the airways, lungs, and pleura, meaning the mechanical and structural side of the chest. Scope: advanced diagnostic and therapeutic bronchoscopy and pleural procedures, centered on lung-cancer diagnosis and staging and on relieving airway/pleural disease.

Sub-subspecialty fellowship of Pulmonary & Critical Care Medicine.

The 30-second version

Interventional pulmonology is the procedural tip of pulmonary medicine, the corner of the field built around the scope and the pleural tray rather than the ventilator or the clinic. When a patient has a suspicious lung mass, a mediastinum full of nodes that needs staging, a tumor choking off a mainstem bronchus, a malignant effusion filling a chest, or a stubborn air leak, the interventional pulmonologist is the one who gets the tissue and opens the airway, using EBUS (endobronchial ultrasound), navigational and increasingly robotic bronchoscopy, rigid bronchoscopy, airway stents, tumor ablation (laser/cryo/argon), endobronchial valves, medical pleuroscopy, and tunneled pleural catheters. It is central to how lung cancer gets diagnosed and staged in this country, and it is one of the hottest, fastest-growing procedural niches in internal medicine, and robotic bronchoscopy alone has reshaped the field in the last few years. The trade at the center of it: you get a genuinely procedural, largely daytime, low-emergent-call career with a real craft, bought with an extra fellowship year on top of an already-long PCCM runway, a job market concentrated in academic and cancer centers, and a reimbursement problem that means the pay premium over general pulmonary is real but smaller than the "proceduralist" label implies. One thing to get straight early: this is certified by a subspecialty society, the AABIP, rather than by an ABMS-recognized board, through a formal fellowship and exam that only recently began earning ACGME accreditation.

Quick dashboard (details and sources below)
Training after med school IM (3) + PCCM (3) + IP (1) = 7 years after med school (or IM + Pulm-only 2 + IP 1 = 6 yrs)
Total from college start ~15 years (4 undergrad + 4 med school + 3 IM + 3 PCCM + 1 IP fellowship)
Training chain Med school (4) → IM residency (3 yr) → Pulmonary/Critical Care fellowship (2–3 yr) → 1 yr Interventional Pulmonology fellowship
Competitiveness (as an Interventional Pulmonology fellowship) Competitive within a small, self-selected pool — 43 programs offered 51 positions in the 2026 NRMP fellowship match and filled 50 of them (98.0%), against 66 applicants, 16 of whom went unmatched ⟳
Typical full-time pay ~$400,000–$460,000 total comp — a modest premium over general pulmonary, driven by wRVU/procedure mix more than the title ⟳
Pay vs. general pulmonary AABIP 2022: academic ~$320k–$350k · private practice ~$428k; on FastRVU's pulmonology model the IP practice mix runs ~$440k–$550k on a wRVU basis, against general/outpatient pulmonary ~$290k–$360k ⟳
Lifestyle Procedure-focused, largely daytime/scheduled; low-acuity, infrequent emergent call — often better than full-time intensivist
Burnout No IP-specific figure; inherits pulmonary (~50%, Medscape 2024) but the scheduled, procedural rhythm tends to buffer it ⟳
% women ~18% of AABIP-surveyed IP physicians (2022) and 20.6% of ACGME IP fellows (AY2024-25) — a notably male-skewed procedural niche ⟳
DO / IMG accessibility Gate is PCCM (relatively DO/IMG-open); of the 50 IP positions filled in the 2026 match, 18 went to US MD grads, 7 to US DO grads, 9 to US IMGs and 16 to non-US IMGs ⟳

What they actually do

Interventional pulmonologists are the proceduralists of the chest. Their core mission is diagnosing and staging lung cancer, using EBUS to sample mediastinal and hilar lymph nodes (the single most important step in staging lung cancer) and navigational or robotic bronchoscopy to reach and biopsy peripheral lung nodules that used to require a surgeon, and relieving structural airway and pleural disease: reopening airways obstructed by tumor, stenting collapsed or strictured airways, ablating endobronchial tumors, managing massive or malignant pleural effusions, and treating air leaks and severe emphysema.12 They are the less-invasive alternative to thoracic surgery for a large and growing list of problems, the person a general pulmonologist, an oncologist, or a thoracic surgeon refers the hard airway and pleural cases to.2

Practically, IP is a referral-and-procedure specialty. You run a procedure-heavy schedule (bronchoscopy suite, endoscopy suite, sometimes the OR for rigid cases) plus a clinic that is mostly IP consults (lung nodules, hemoptysis, airway complaints, pleural disease, pre-procedure evaluation), and you coordinate tightly with oncology, radiation oncology, thoracic surgery, and radiology inside a multidisciplinary lung-cancer program. The honest structural reality (and it matters for the whole career): pure, IP-only jobs exist but are uncommon and concentrated at large academic/cancer centers. Many IP physicians in the community still carry general pulmonary clinic and some ICU coverage. The fellowship adds a procedural skillset on top of PCCM, it doesn't usually erase the rest of the PCCM job.34

Representative procedures / hands-on work (this is the identity of the field):

  • Diagnostic/sampling: linear EBUS with transbronchial needle aspiration (mediastinal staging) · electromagnetic navigational bronchoscopy and robotic bronchoscopy for peripheral nodules · transbronchial cryobiopsy (an alternative to surgical lung biopsy for ILD) · radial EBUS · medical pleuroscopy / thoracoscopy (inspect and biopsy the pleura).12
  • Therapeutic: rigid bronchoscopy · airway stenting (silicone and metallic) · endobronchial tumor ablation (laser, argon plasma coagulation, cryotherapy, microdebridement) · endobronchial valves for bronchoscopic lung-volume reduction (severe emphysema) and persistent air leaks · bronchial thermoplasty for severe asthma · whole-lung lavage for pulmonary alveolar proteinosis · tunneled/indwelling pleural catheters and pleurodesis for recurrent effusions · percutaneous tracheostomy.12

A day in the life (IP procedure day): A block of scheduled cases: an EBUS staging bronchoscopy for a new lung-cancer diagnosis, a robotic bronchoscopy to biopsy a peripheral nodule, a rigid bronchoscopy to debulk and stent a tumor obstructing a mainstem bronchus, a pleuroscopy with talc pleurodesis, a couple of tunneled pleural catheter placements. Cases run under moderate sedation or general anesthesia with anesthesia support; you're on your feet, hands-on, reading ultrasound and airway anatomy in real time, and the work is technical and tactile in a way clinic pulmonary is not. A clinic day is IP consults: lung nodules needing a biopsy plan, hemoptysis, airway stenosis follow-ups, malignant effusion management, tumor-board prep. The rhythm is much more like a proceduralist's (scheduled lists, elective cases, predictable daytime hours) than like an intensivist's, which is a big part of the draw, and a big part of why it's pitched as a longevity/off-ramp move within PCCM.34

The training path & time to completion

Interventional pulmonology sits at the end of one of the longest training chains in medicine. The full path: medical school (MD or DO, 4 yrs) → Internal Medicine residency (3 yrs) → Pulmonary & Critical Care (3 yrs) or Pulmonary-only (2 yrs) fellowship → 1-year Interventional Pulmonology fellowship → IP board certification via the AABIP.156 This is a three-step entry built on top of a subspecialty: you must first match IM, then match PCCM, then match IP. There is no shortcut.

  • **It's a sub-subspecialty fellowship. You are already a board-eligible (or board-certified) pulmonologist/intensivist before you start the IP year. The fellowship is a focused, high-volume procedural year of hundreds of advanced bronchoscopic and pleural procedures, layered on the bronchoscopy skills you began building in PCCM.13
  • Fellowship length: 1 year. A small number of programs offer an optional second/research year, but one dedicated clinical year is the standard.56
  • Prerequisite: completion of an ACGME Pulmonary & Critical Care (or Pulmonary Disease) fellowship is the standard route. (Thoracic surgery has historically had its own airway-procedural overlap, but the AABIP IP pathway is built for pulmonary-trained physicians.)56
  • The accreditation story, read carefully, is the field's defining structural quirk. IP was for years a non-ACGME subspecialty: training programs and board certification were organized by the specialty society, the American Association for Bronchology and Interventional Pulmonology (AABIP) and the Association of Interventional Pulmonology Program Directors (AIPPD), not by the ABMS/ACGME system that governs most fellowships.57 That has now flipped: ACGME recognized IP as a new subspecialty in the early 2020s and finalized program requirements, and on the AABIP program list dated 22 April 2026, 46 of the 47 accredited IP programs are ACGME-accredited (the remaining one holds AABIP/AIPPD accreditation through 30 June 2026, and three further programs on that list are accredited by neither body).67 To sit the board you must graduate from a program that is AABIP/AIPPD- or ACGME-accredited; the older "practice pathway" that once let physicians certify without a dedicated fellowship closed (the last year certifiable without the 1-year fellowship was 2016, and the clinical practice pathway closed at the end of 2024).57 Selection already runs through the NRMP Medical Specialties Matching Program, and applications are transitioning from the society's own IPFAS system to ERAS for the 2027 cycle, a clear sign of the field formalizing and mainstreaming.6
  • Board: AABIP Interventional Pulmonology board certification, a society board exam offered since 2013, against a published blueprint, with maintenance/recertification requirements (e.g., attesting to ~100 IP procedures over two years, balanced across airway and pleural work).57 Note the honest caveat: IP is not yet an ABMS-recognized subspecialty. ABIM has a proposed ABMS-recognized IP subspecialty certificate in the pipeline (public comment closed May 2025; a Board decision no sooner than Spring 2026, then ABMS approval and exam build over "typically several years"), but as of mid-2026 the operative credential is the AABIP exam, and an ABIM/ABMS certificate is coming, not here.78 This is part of why benchmark data (pay, demographics) is thinner than for ABMS fields.
  • Total from the start of college: ~15 years (4 undergrad + 4 med school + 3 IM + 3 PCCM + 1 IP). This is among the longest runways in all of medicine, one year longer than combined PCCM, which is itself ~14 years.

How competitive is it? (as an Interventional Pulmonology fellowship)

Competitiveness in IP is unusual and easy to misread, because the applicant pool is tiny and self-selected. You're only in it if you've already committed years to PCCM and specifically want a procedural career. NRMP publishes a row for IP every year in its Specialties Matching Service report, and the numbers are below.

  • A small field. There are 47 accredited IP fellowship programs in the US (the AABIP's April 2026 list carries 50 rows, three of them accredited by neither body), each typically taking 1 fellow/year (43 of them entered the 2026 match and filled 50 seats between them), so the national output is about 50 IP fellows per year, a small fraction of the PCCM class.6910 ⟳
  • The match numbers. IP ran its own application system for years (the "IPFAS" system), selection now runs through the NRMP Medical Specialties Matching Program, and applications move to ERAS for the 2027 cycle.6 For 2026 appointments, 43 programs offered 51 positions and filled 50, a fill rate of 98.0%, against 66 applicants. One program was left with an unfilled position, and 16 of the 66 applicants matched nowhere. The five-year fill rate has not gone below 93.6% (93.6% in 2022, 100% in both 2023 and 2024, 97.7% in 2025, 98.0% in 2026), and applicants have outnumbered positions every one of those years.10 ⟳
  • The honest read: because the pool is small and self-selected, IP isn't "competitive" in the cardiology-fellowship sense of thousands chasing few spots, but with roughly one seat per program, the best programs (high procedural volume: major cancer centers, transplant/academic hubs) are genuinely selective, and strong bronchoscopy exposure, research, and mentorship in PCCM matter a lot for landing one.34 The competitive question here isn't "can a qualified, motivated PCCM grad get an IP spot" (broadly, yes). It's "is the extra year and the academic/geographic concentration worth it for the job you actually want" (see Culture and the FLI angle).

Board: AABIP Interventional Pulmonology certification (society board since 2013; ACGME accreditation of fellowships now the majority, and an ABIM/ABMS certificate proposed but not yet live).578

Compensation — the robust version

Here's the fact that reframes the field: IP pays more than general outpatient pulmonary, but the premium is driven by procedure and wRVU volume rather than by the "interventional" title, and it is nowhere near the interventional-cardiology-style windfall the name suggests. The reason is structural and well-known inside the field: IP procedures are under-reimbursed. Bronchoscopy and even navigational bronchoscopy pay modestly relative to the time and skill they demand (navigational bronch reimburses at roughly half a laparoscopic appendectomy while taking 2–3× as long), and there is no high-volume, high-margin emergency procedure, no "STEMI equivalent," to drive income the way it does in interventional cardiology or GI. Many hospitals value IP less as a profit center than as a service that keeps lung-cancer patients inside the system for oncology and surgery, and academic centers frequently subsidize IP salaries for that reason.348 Always read these numbers against general pulmonary and combined PCCM, because those are the real comparisons an IP fellowship is competing with.

The primary benchmark is the AABIP 2022 Compensation & Practice Report (survey of AABIP physician members; the best IP-specific data that exists, though thin at a ~28% response rate, and IP isn't ABMS-tracked):8

  • Academic median total comp by rank: assistant professor $320,000 · associate professor $338,000 · full professor $350,000. ⟳
  • Private practice median: $428,000. A clear premium over academic IP. ⟳
  • wRVU targets (used less than half the time in IP, and set low to reflect IP's under-valued procedure codes): academic median 5,500 wRVU · private 6,300 wRVU.8 ⟳
  • A documented gender pay gap: in academics, women earned roughly $57,000 less than men after adjusting for career length (P=0.003).8 ⟳

Cross-check against the productivity benchmarks (parent-field basis). FastRVU's pulmonology page, an aggregator's planning model rather than a licensed survey, puts the interventional-pulmonology practice mix around $440,000–$550,000 at 7,500–9,000 wRVU, the top of the pulmonary compensation range and above general/outpatient pulmonary (~$290k–$360k).11 Aggregators run higher and noisier (MaritHealth ~$506k; ZipRecruiter title-matched figures), so treat those as ceilings rather than typicals, given the thin IP-specific sampling.12 ⟳

A defensible "typical full-time" figure for 2025–26 is ~$400,000–$460,000 total comp, landing above general pulmonary and at or modestly above combined PCCM, with private-practice and high-volume-procedural roles reaching the high-$400s to ~$550k, and academic junior faculty starting in the low-$300s.811 ⟳

The levers that actually move IP pay:

  • Procedure volume and case mix. High-complexity bronchoscopy and pleural volume is the engine; this is a wRVU-driven field.11
  • Private vs. academic. The AABIP data show private practice ($428k) well above academic ($320k–$350k), the reverse-of-glamour pattern where the academic prestige jobs pay least.8
  • Whether the job is pure IP or hybrid. Many community IP roles bundle general pulmonary clinic and some ICU/critical-care billing, which raises total comp (CC acuity and shift pay) even as it dilutes the "pure IP" identity.34
  • New-technology programs. Robotic bronchoscopy and structured lung-nodule/lung-cancer-screening programs are expanding volume and, at well-run centers, the case base that supports an IP salary.1

The community counterpoint. Experienced IPs online bluntly peg the marginal pay bump for the extra fellowship year at close to nothing, and call standalone IP "a money loser by itself" because of weak bronchoscopy reimbursement, which is why most bundle IP with general pulm, ICU, and clinic work. That squares with the AABIP report's "low-wRVU procedures" finding. Frame it honestly: you do IP for the work and the thoracic-oncology niche, not for a big raise.348

Geography (inherit from parent pulmonary; no IP-specific table exists, so limited data): parent pulmonary/PCCM shows an inverse pattern (coastal/academic below average; Midwest/Sun Belt/rural above), but IP jobs cluster where referral and procedural volume exist (metros/academic and cancer centers), which can cap the rural premium that general pulmonary and critical care enjoy.11 ⟳

Trend: demand for advanced diagnostics is rising fast (lung-cancer screening is catching more nodules that need biopsy; robotic bronchoscopy is proliferating), which is growing IP volume and jobs, but reimbursement reform has lagged the technology, so the field's income is more likely to rise through case volume and hospital investment than through better per-procedure pay. ACGME accreditation is unlikely to change the reimbursement math directly (procedure coding/valuation sits with the RUC, which has historically favored surgical codes).38 ⟳

Lifestyle

IP's lifestyle is, for many, the quiet selling point, and it's a genuinely different bargain from the rest of PCCM. This is a scheduled, procedural, largely daytime job rather than an ICU-shift job. Your week is built around elective procedure lists and IP clinic, not around 7-on/7-off nights covering a crashing unit.34

Hours are procedural-specialist hours: busy, hands-on days in the bronchoscopy and endoscopy suite plus clinic, generally in the daytime band. Call is the standout feature: it's light and low-acuity by the standards of PCCM. Because there is no true "STEMI equivalent," emergent overnight IP procedures (a crashing central-airway obstruction, massive hemoptysis) are real but infrequent, and IP call rarely means a stream of middle-of-the-night cases the way stroke or interventional-cardiology call can.3 Compared with a full-time intensivist carrying ICU nights and weekends, IP is widely described online as the more sustainable, controllable procedural life within pulmonary.34

The catch is the hybrid reality. If your job is pure IP at an academic/cancer center, the lifestyle is clean and controllable. If you're in a community or smaller-academic role that bundles general pulmonary clinic and ICU coverage to justify the hire, you inherit that schedule too, with nights, weekends, and critical-care intensity on top of your procedure days. So the honest lifestyle read is bimodal and job-design-dependent: IP can be one of the better procedural lifestyles in internal medicine, but only if the position is structured that way.34

Lifestyle rating: 3.5/5. Meaningfully more controllable than full-time critical care (scheduled cases, light emergent call, daytime rhythm), and a real reason people use IP as a longevity move off ICU nights; docked from higher because the field is academic/geographically concentrated and many real-world jobs still bundle general pulm and ICU coverage that pulls the schedule back toward standard PCCM.

Wellbeing — the part to take seriously

Burnout. There is no clean IP-specific burnout percentage, because the field is too small and too new to appear in the Medscape specialty tables (limited data). Read two signals together. First, the parent field, and the two halves of it disagree: Medscape 2024 put pulmonary medicine at 50%, just above its 49% all-physician average and inside its ten highest-burnout specialties, and critical care at 45%, below that average and inside its ten lowest.13 Second, and directionally important: the drivers of PCCM burnout that hit hardest, meaning ICU moral distress, futile-care family battles, and relentless nights, are exactly what IP moves you away from. A scheduled, procedural, mostly-daytime practice with light emergent call plausibly buffers the specific burnout mechanisms that grind down intensivists, though it introduces its own (procedural pressure, the frustration of under-reimbursed work, and the emotional weight of a patient population that is heavily lung-cancer). Net read: baseline distress is roughly parent-pulmonary level, likely eased by the schedule but not immune. Do not assert an IP-specific number that doesn't exist. ⟳

Satisfaction. The best IP-specific signal is encouraging: in the AABIP survey, most interventional pulmonologists report satisfaction with their career choice, consistent with a self-selected group who chose an extra year specifically to do the procedural work they love.8 The recurring community theme matches: people who did IP because they're genuinely passionate about advanced bronchoscopy and pleural procedures tend to be glad they did; the regret stories cluster around people who expected interventional-cardiology money or an easy pure-IP job and hit the reimbursement/geography reality instead.34

Emotional load. IP is deeply enmeshed in lung cancer, and much of the work is delivering, or setting up, a cancer diagnosis and staging, and managing the airway and pleural complications of advanced malignancy. That's meaningful, high-impact work, but it carries the emotional weight of an oncology-adjacent practice. The flip side of PCCM's ICU moral distress is largely absent (far fewer prolonged futile-care/end-of-life ICU battles).

Career longevity is genuinely favorable, and that's much of the point. IP is frequently framed within PCCM as a longevity and off-ramp move: it lets a pulmonologist build a procedural identity that gets them off the ICU-nights treadmill while keeping high-value, intellectually engaging hospital work. The limiter is physical: advanced bronchoscopy and rigid cases are demanding, standing procedural work, and like any proceduralist you have to sustain the hands and the volume, but the absence of relentless overnight critical-care coverage makes IP one of the more sustainable ways to age within pulmonary medicine.3

Who's in the field (demographics)

IP-specific demographic data is thin. NRMP's match table reports applicant type but not gender or race. ACGME's Data Resource Book now carries an interventional pulmonology row with a sex breakdown, and past that the AABIP survey plus parent-field figures are the best available for what the match does not cover.

  • Women: the AABIP 2022 survey was 17.8% women among responding IP physicians, a notably male-skewed procedural niche, and ACGME's IP fellow row runs the same way at 20.6% (7 of 34, AY2024-25). The parent fields sit well above both: PCCM fellows are 40.0% women (977 of 2,445) and IM residents 46.1% (15,730 of 34,086) in the same ACGME book.814 The pattern echoes other procedure-heavy fields, and the survey documented a real gender pay gap in academics ($57k).8 The AABIP figure comes from a self-selected survey of a small field rather than being a claim about who should be in it. ⟳
  • DO / IMG: NRMP publishes the composition of the matched class. Of the 50 IP positions filled for 2026 appointments, 18 (36.0%) went to US MD graduates, 7 (14.0%) to US DO graduates, 9 (18.0%) to US IMGs, and 16 (32.0%) to non-US IMGs, so nearly two-thirds of the incoming class trained outside a US MD school. That is a more open picture than "small, academic, and selective" suggests, and it is consistent with the gate, PCCM, being relatively DO- and IMG-accessible for a competitive IM fellowship (~17% DO, ~41% IMG of matched PCCM fellows, NRMP 2025).1110 ⟳
  • URiM: no IP-specific data (limited data). Parent PCCM shows persistent URiM under-representation (~10% of fellows, below the ~13.7% UIM share of IM residents), and procedural sub-subspecialties generally track or lag that. ⟳

Culture, personality & the online stereotypes

Who gravitates here: pulmonologists who fell in love with the scope and the procedure room, the ones who, during PCCM, found themselves happiest doing bronchoscopy and pleural work and wanted more of it, done better. They tend to be technically-minded, craft-oriented people who like a tactile, hands-on, "fix the airway / get the tissue" job and the visible, immediate result of reopening an obstructed airway or draining a chest. Many are drawn specifically to lung-cancer care and multidisciplinary oncology work, and to being on the cutting edge of new technology (robotic bronchoscopy is a genuine magnet). And a meaningful share are making a deliberate lifestyle and longevity choice, trading the ICU-nights grind for a scheduled proceduralist life. As always, plenty of people in the field don't fit any single mold.34

The stereotypes. Community perception rather than fact. Each carries a kernel and an unfair edge, and plenty of people do not fit the mold:

  • "The surgeons of pulmonary / the proceduralists who didn't want the ICU." The read online is that IP is where the procedure-loving, gadget-loving pulmonologists go, the ones who'd rather be scoping than running a code at 3am. Kernel of truth (it is the procedural, off-the-nights corner of the field); unfair edge in implying they can't or won't do critical care, since most trained fully in it and many still do it.
  • "Chose it for the robots and the toys." IP is genuinely tech-forward (EBUS, navigation, robotic bronchoscopy, stents, valves), and the enthusiasm for new platforms is real, but the caricature undersells how much of the job is careful oncologic diagnosis, staging, and hard airway/pleural judgment, not gadget play.
  • "Did an extra year for a title that doesn't pay like one." A recurring, pointed community jab that IP's reimbursement doesn't match its skill: that you add a year and a hard skillset for a premium that's modest and a job market that's narrow. It's a real, live debate rather than a settled verdict, and much less true for people who wanted the procedural craft and lifestyle for their own sake, and who land a well-run high-volume program.
  • "An academic-only specialty." The perception that you can only really do IP at a big cancer center. There's a strong kernel (pure-IP jobs are concentrated there), but community-academic and hybrid roles exist and are slowly growing with robotic-bronch adoption.

What people say online (synthesized and paraphrased, not quotes): Across trainee and physician forums, the dominant, blunt recurring debate is "is the extra year worth it?" The pro camp: if you love procedures and want a scheduled, low-emergent-call, sustainable proceduralist life off the ICU-nights treadmill, IP is a genuinely rewarding craft and one of the coolest procedural niches in IM, and robotic bronchoscopy is making it hotter and more available. The skeptic camp is equally consistent and specific: reimbursement is the field's Achilles' heel (procedures pay poorly for the time/skill; no high-margin emergency; hospitals treat IP as a loss-leader to keep cancer patients in-house), pure-IP jobs are scarce and academic/geographically concentrated (many community jobs make you do general pulm and ICU anyway), and the pay premium over general PCCM is real but modest, rather than the interventional-cardiology payoff the name implies. There's broad agreement the training is excellent and the demand for the diagnostics is climbing fast; the disagreement is whether the extra year plus the geographic/pay constraints pencil out for you specifically. The through-line: choose it because you love the procedural work and want the lifestyle, not as a financial upgrade.34

Voices from the field. Paraphrased from public writing, with links to the originals:

  • The Student Doctor Network "Future Prospects of Interventional Pulmonology" thread. Practicing pulmonologists stress-test the field and land on a nuanced read: IP is largely academic/tertiary-center work tied to cancer programs, pure-IP jobs are uncommon, reimbursement is the core weakness (no STEMI-equivalent; navigational bronch under-pays), and it's worth it mainly for those genuinely passionate about procedures who'll accept academic employment, geographic constraints, and a modest pay premium, but the lifestyle (scheduled, light emergent call) can beat full-time critical care.3
  • The SDN "How does interventional pulm differ from regular pulm?" thread. Community consensus that IP adds advanced techniques (rigid bronch, stents, ablation, tracheostomy) beyond routine PCCM bronchoscopy/EBUS, that most IPs run hybrid practices (procedures + clinic ± ICU) rather than pure procedural careers, that reimbursement often makes institutions subsidize IP salaries to retain oncology patients, and that high-volume programs give far better training than low-case fellowships.4
  • The AABIP 2022 Compensation & Practice Report (Journal of Bronchology & Interventional Pulmonology). The field's own benchmarking: academic comp ~$320k–$350k by rank vs. private $428k, low/underused wRVU targets reflecting under-valued IP codes, a documented academic gender pay gap ($57k), and, notably, most respondents satisfied with their career choice, in a field still unrecognized by the ABMS.8
  • The AABIP board-certification and eligibility materials document the field's formalization arc: an introductory certification pathway that closed to non-fellowship-trained physicians after 2016, a clinical practice pathway closed at the end of 2024, accreditation now required (AABIP/AIPPD or, for the majority of programs, ACGME), and a transition to ERAS for the 2027 application cycle, a subspecialty maturing from society-run niche toward mainstream fellowship.57

Why people choose it / why people leave

Why choose it: you love advanced bronchoscopy and pleural procedures and want a genuinely procedural pulmonary career · a scheduled, largely daytime, low-emergent-call life that's more sustainable than full-time ICU (a real off-ramp from the nights) · a central, high-impact role in lung-cancer diagnosis and staging and multidisciplinary oncology care · one of the hottest, fastest-growing tech frontiers in IM (robotic bronchoscopy, navigational biopsy, valves) · a modest but real pay premium over general pulmonary · a distinctive, respected craft and skillset few others have.

Why leave or avoid it: the reimbursement problem, since procedures pay poorly for the time and skill, there's no high-margin emergency, and hospitals often treat IP as a loss-leader, so the pay premium is smaller than the "interventional" label implies · pure-IP jobs are scarce and academically and geographically concentrated, and many community roles bundle general pulm and ICU coverage anyway · an extra fellowship year on top of an already ~14-year PCCM runway (opportunity cost is real) · a non-ABMS society board (formalizing, ABIM certificate proposed, but still) · the emotional weight of an oncology-heavy practice.

Best fit if: the procedure room is where you're happiest · you want a scheduled proceduralist life and want off the ICU-nights treadmill · you're energized by lung-cancer diagnostics and new technology · you're willing to go where the (largely academic/cancer-center) jobs are · you want the craft for its own sake, not a financial windfall.

Not for you if: you need a broad menu of jobs in any location · you're doing it mainly for money (the premium over general PCCM is modest, and there's no interventional-cardiology payoff) · you can't stomach one more fellowship year of opportunity cost · you want to stay a generalist pulmonologist/intensivist · you dislike a heavily oncology-focused patient population.

The FLI angle — Interventional Pulmonology for first-gen, low-income & immigrant students

Where it fits FLI realities well:

  • The gate (PCCM) is genuinely reachable. IP sits on top of pulmonary/critical care, which is reached through the standard IM residency (one of the most DO- and IMG-open routes in medicine) and a PCCM fellowship that, while competitive, is markedly more DO/IMG-accessible than cardiology or GI. For a first-gen, DO, or IMG physician who falls in love with bronchoscopy, this is a plausible summit to aim for rather than a closed door.11
  • A distinctive, in-demand skillset = security. Advanced diagnostics are a growth area (lung-cancer screening + robotic bronchoscopy are expanding case volumes), so the procedural skill is durable and increasingly sought, with real job security once you're in.
  • A more sustainable proceduralist life. For someone who needs a long, stable career (not a body-breaking one), IP's scheduled, low-emergent-call rhythm, off the ICU-nights treadmill, is a genuine longevity advantage over full-time critical care.
  • PSLF fits the employer base. IP is concentrated in academic medical centers and large hospital and cancer programs, exactly the 501(c)(3) nonprofit employers that qualify for Public Service Loan Forgiveness, so 10 years of qualifying payments toward forgiveness is very achievable on this path. Ground it honestly: most physicians carry ~$200k+ in student debt; PSLF is a real but paperwork-heavy lever, not a guarantee.

Risks to name honestly:

  • The longest runway in the building. ~15 years from the start of college, one more fellowship year than combined PCCM, at low trainee pay before attending income begins. For a student who needs to start earning and supporting family fast, that extra year, chasing a modest premium over a PCCM salary you could already command, is a real trade-off. Be clear-eyed: the financial ROI of the IP year specifically is thin.8
  • Geographic concentration collides with family/status ties. The best (and often the only pure) IP jobs are at academic/cancer centers in specific cities. If family, community, or immigration status ties you to a particular place, a narrow, location-constrained job market is a serious consideration. General PCCM travels almost anywhere; pure IP does not.3
  • Reimbursement risk is structural, not personal. IP's under-valued procedure codes are a system feature rather than something hard work fixes. Go in understanding the pay premium is modest and volume-driven, and that many jobs will still ask you to do general pulm/ICU to make the economics work.38

Bottom line: IP is a reachable summit for a first-gen, DO, or IMG physician who genuinely loves the procedural craft, built on the accessible PCCM pathway, in a growing, in-demand niche, with a sustainable schedule and PSLF-friendly employers. But be honest about the trade: it's an extra year at the end of an already-15-year road, for a modest pay premium over general PCCM, in a job market concentrated at academic cancer centers. Choose it because the bronchoscopy suite is where you want to spend your career, rather than as a financial or accessibility shortcut. Shadow a full IP procedure day, and ask any prospective employer exactly how "pure" the IP job really is, before you commit.

Fun facts

  • IP is one of the few subspecialties whose board certification has been run by a specialty society (the AABIP, since 2013) rather than the ABMS, a mature "society board" that only in the mid-2020s added ACGME accreditation of its fellowships (46 of the 47 accredited programs are now ACGME), with ERAS applications arriving for the 2027 cycle and an ABIM/ABMS certificate proposed but not yet live.
  • EBUS (endobronchial ultrasound) made the interventional pulmonologist central to lung-cancer staging. Sampling mediastinal lymph nodes through the airway wall replaced a lot of surgical mediastinoscopy.
  • Robotic bronchoscopy. A scope driven with a game-controller-like interface to reach tiny peripheral lung nodules, is the technology that has most reshaped the field in the last few years, and a big reason it's a "hot, growing" niche.
  • Whole-lung lavage for pulmonary alveolar proteinosis is exactly what it sounds like: physically washing out an entire lung, liters at a time, while the other lung keeps the patient alive, is one of the more dramatic procedures in all of medicine.
  • IP's central economic paradox: hospitals often value it not as a profit center but as a service that keeps lung-cancer patients inside the system for oncology and surgery, which is why academic centers frequently subsidize IP salaries.
  • The last year you could be IP board-certified without a dedicated 1-year fellowship was 2016, and the field deliberately closed its own back doors to raise the bar.

Sources

Footnotes

  1. Scope and procedures of interventional pulmonology (EBUS, navigational and robotic bronchoscopy, cryobiopsy, rigid bronchoscopy, airway stenting, tumor ablation, endobronchial valves, bronchial thermoplasty, whole-lung lavage, tunneled pleural catheters, medical pleuroscopy, percutaneous tracheostomy) and its centrality to lung-cancer diagnosis/staging. Wikipedia, "Interventional pulmonology" (https://en.wikipedia.org/wiki/Interventional_pulmonology); see also the pulmonary and critical care medicine profile on this site. (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  2. Interventional pulmonology as a less-invasive alternative to thoracic/VATS surgery for neoplastic and non-neoplastic airway, lung, and pleural disease; endoscopy-suite/bedside settings under sedation. Wikipedia, "Interventional pulmonology" (https://en.wikipedia.org/wiki/Interventional_pulmonology); AABIP, "General Interventional Pulmonology" (https://www.aabronchology.org/general-interventional-pulmonology). (accessed 2026). ↩ ↩2 ↩3 ↩4

  3. Student Doctor Network forum, "Future Prospects of Interventional Pulmonology" — paraphrased community sentiment: largely academic/tertiary-center field tied to cancer programs, pure-IP jobs uncommon, reimbursement the core weakness (no STEMI-equivalent; navigational bronch under-pays ~half a lap appy for 2–3× the time), hospitals value IP as an oncology-retention service, pay trails procedural-ownership pulmonary/CC, but lifestyle (scheduled cases, light emergent call, no mandatory ICU in pure roles) can beat full-time critical care; marginal pay bump for the extra year pegged near zero, IP "a money loser by itself" standalone. https://forums.studentdoctor.net/threads/future-prospects-of-interventional-pulmonology.1491240/ (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19

  4. Student Doctor Network forum, "How does interventional pulm differ from regular pulm?" — paraphrased: IP adds advanced techniques (rigid bronch, stents, ablation, tracheostomy) beyond routine PCCM bronchoscopy/EBUS; most IPs run hybrid practices (procedures + clinic ± ICU), few pure-procedural roles; reimbursement often prompts institutions to subsidize IP salaries to retain oncology patients; academic median ~$270k cited, private higher; high-volume programs train better. https://forums.studentdoctor.net/threads/how-does-interventional-pulm-differ-from-regular-pulm.1249162/ (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13

  5. AABIP, "History of IP Board Certification" and IP Board Eligibility Criteria — first IP fellowship in North America opened 1996; AIPPD founded 2012; AABIP board exam developed 2013; 1-year dedicated IP fellowship required (last year certifiable without it was 2016; clinical practice pathway closed 12/31/2024); certification requires graduating from an accredited (AABIP/AIPPD or ACGME) IP fellowship; recertification requires ~100 IP procedures over 2 years (balanced airway/pleural). https://www.aabronchology.org/board-certification ; https://www.aabronchology.org/ip-board-eligibility-criteria (accessed 2026). Field history corroborated by "Interventional Pulmonary Fellowship Training: End of the Beginning," ATS Scholar 2023;4(4):405 (https://academic.oup.com/atsscholar/article/4/4/405/8364145). ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8

  6. AABIP/AIPPD Interventional Pulmonology accreditation list (dated 22 Apr 2026) and IP Fellowship Program Contact Information — 50 programs listed, of which 46 are marked ACGME-accredited, 1 is AABIP/AIPPD-accredited through 30 June 2026 (Chicago Chest Center), and 3 are marked "program not accredited" (LSU Health Shreveport, University of Colorado, University of Kentucky), so 47 accredited programs in all; ~1 fellow/program/year (small national output); formal match via NRMP Medical Specialties Matching Program; application transitioning from IPFAS to ERAS beginning the 2027 cycle. https://www.aabronchology.org/aabip-aippd-interventional-pulmonology-accredidation ; https://www.aabronchology.org/ip-fellowship-program-contact-information ; ACGME Program Requirements for GME in Interventional Pulmonology (2025 reformatted) https://www.acgme.org/globalassets/pfassets/programrequirements/2025-reformatted-requirements/138_interventionalpulmonology_2025_reformatted.pdf (accessed 2026). Corrected 2026-08-17: this page said "44 of 46 accredited IP programs are ACGME-accredited (one remaining AABIP/AIPPD program, one unaccredited)" in six places, including the training bullet, the training-path figure brief, the competitiveness bullet and Fun facts. Counting the rows on the 22 April 2026 list gives 46 ACGME, 1 AABIP/AIPPD and 3 unaccredited of 50 listed. The direction of the accreditation story was right; every count in it was wrong. ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  7. AABIP board-certification structure and the field's (current) non-ABMS status; introductory pathway closed after 2016, clinical practice pathway closed 12/31/2024; exam blueprint and recertification; ACGME accreditation now the majority of programs. AABIP, "History of IP Board Certification" (https://www.aabronchology.org/board-certification); AABIP/AIPPD accreditation page (https://www.aabronchology.org/aabip-aippd-interventional-pulmonology-accredidation). (accessed 2026). ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7

  8. AABIP 2022 Interventional Pulmonology Productivity, Compensation, and Practice Benchmarks Report — survey of AABIP members (~28.3% response; ~17.8% women); academic median comp assistant $320k / associate $338k / full $350k; private practice median $428k; wRVU targets academic 5,500 / private 6,300 (used <half the time, set low to reflect under-valued IP codes); academic gender pay gap ~$57,175 (P=.003); most satisfied with career choice; IP not ABMS-recognized (limited benchmark data). J Bronchology Interv Pulmonol (2022/2023). https://pubmed.ncbi.nlm.nih.gov/36825802/ (accessed 2026). ⟳ ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16

  9. Program count / small-field context — AABIP program list (47 accredited programs on the April 2026 list, 46 of them ACGME-accredited, of 50 rows in total) and representative fellowships (Duke, Mayo, Cleveland Clinic, MSKCC, Johns Hopkins, UCSD, Stanford, Northwestern) typically taking ~1 fellow/year. https://www.aabronchology.org/ip-fellowship-program-contact-information ; Mayo Clinic FL IP Fellowship (1 yr, 1 competitive seat, NRMP MSMP, prereq Pulm/PCCM) https://college.mayo.edu/academics/residencies-and-fellowships/interventional-pulmonology-fellowship-florida/ (accessed 2026). ⟳ ↩

  10. Interventional pulmonology match data — NRMP, Results and Data: Specialties Matching Service 2026 Appointment Year, February 2026, Table 1A: 43 programs, 51 positions offered, 50 filled (98.0%), 66 applicants, 1 program with at least one unfilled position, 16 applicants unmatched (75.8% of applicants matched; 1.3 applicants per position). Table 2, composition of the 50 filled positions: 18 US MD graduates (36.0%), 7 US DO graduates (14.0%), 9 US IMGs (18.0%), 16 non-US IMGs (32.0%). Five-year trend page (p. 75): positions offered/filled 47/44 in 2022, 45/45 in 2023, 43/43 in 2024, 44/43 in 2025, 51/50 in 2026; applicants 51, 66, 62, 51, 66. https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf (2026). Correction, 2026-08-13: this page previously said IP "is not measured through the big NRMP Match tables," that clean fill-rate and applicant-to-position tables "don't yet exist in the same form," that there were "no clean IP-specific match demographics," and that an NRMP match was still arriving with ERAS in 2027. NRMP has published an IP row every year for at least five; only the ERAS application system is new for 2027. ⟳ ↩ ↩2 ↩3

  11. Interventional-pulmonology practice-mix compensation on an MGMA/wRVU basis (~$440k–$550k at ~7,500–9,000 wRVU; above outpatient pulmonary $290k–$360k and combined PCCM ~$400k–$430k), the wRVU-driven structure, and PCCM DO/IMG accessibility (~17% DO, ~41% IMG of matched fellows, NRMP SMS 2025). Compensation figures are MGMA 2025 by way of FastRVU pulmonology, https://fastrvu.com/specialties/pulmonology; the DO and IMG fellow shares are NRMP's Specialties Matching Service 2025 Appointment Year report, and the current edition is Results and Data: Specialties Matching Service 2026 Appointment Year, February 2026, https://www.nrmp.org/wp-content/uploads/2026/02/SMS_Results_and_Data_Report2026.pdf. See also the pulmonary and critical care medicine profile on this site, which is a cross-reference rather than a source. (2026). ⟳ Corrected 2026-08-17: the body and the compensation figure brief also carried a combined-PCCM comparison band of ~$400k–$430k attributed to this source, which publishes no such figure; it has been removed rather than re-sourced. The dashboard separately put parent pulmonary at ~$395k while the body and the figure brief used ~$290k–$360k, so the page named two different parent fields and the size of the premium moved by $35k–$105k depending on which one a reader saw; the dashboard now carries the body's band. The "MGMA basis" label has come off the body and the figure brief, because MGMA's own subspecialty tables are paywalled and these figures reach the page through the aggregator named above. The $290k–$360k band is itself assembled from that aggregator's early-career floor and its median rather than from the general-pulmonology figure the same page uses for this comparison, and repairing it would mean quoting an excluded host more accurately, so it is left standing and logged for a licensed survey. Corrected 2026-08-17: a figure of this kind stays with the host named rather than being removed, so FastRVU is now named in the visible sentence at the dashboard row and at the cross-check paragraph where these bands appear, and the reader learns what they rest on where they read them. That answer also lifts the block on the $290k–$360k band recorded above: re-quoting the same host more accurately is now permitted, so the band can be rebuilt from that page's general-pulmonology figure rather than from its early-career floor and median. This naming pass did not make that change, and the repair is still outstanding. ↩ ↩2 ↩3 ↩4 ↩5 ↩6

  12. Aggregator IP salary figures (treat as noisy ceilings given thin IP-specific sampling) — MaritHealth ~$506k (https://www.marithealth.com/o/-/interventional-pulmonologist/salary); ZipRecruiter "Interventional Pulmonologist" (https://www.ziprecruiter.com/Salaries/Interventional-Pulmonologist-Salary). (accessed 2026). ⟳ On Marit Health: it publishes a panel of self-reported physician salaries, and displays MGMA and AMGA benchmarks beside them that are masked unless you create an account. The figure quoted here comes from the self-reported panel, not from either benchmark. Read it as crowd data: unweighted, of unstated sample size, and directional. ↩

  13. Parent-field burnout: pulmonary medicine 50% and critical care 45%, against an all-physician average of 49%. Medscape Physician Burnout & Depression Report 2024, n=9,226, fielded July–October 2023. The report is paywalled and returns HTTP 402, so the figures reach this page through relays that agree on the edition, the instrument and every row — Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty), Med School Insiders (https://medschoolinsiders.com/pre-med/every-doctor-specialty-ranked-by-burnout/), Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout) and Becker's ASC (https://www.beckersasc.com/asc-news/the-20-physician-specialties-with-the-highest-lowest-burnout-rates/). No IP-specific burnout figure exists (limited data). Corrected 2026-08-17: the body gave both figures and then described them as "high". Pulmonary's 50% is above the 49% average and appears in Medscape's ten most burned-out specialties; critical care's 45% is four points below it and appears in the ten least, alongside pathology, otolaryngology and orthopedics. The characterization fit one of the two numbers the sentence had just given. ⟳ ↩

  14. ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21 (active residents and fellows by specialty, subspecialty and sex), read directly: interventional pulmonology 41 programs, 34 fellows, 7 women (20.6%), 27 men (79.4%); pulmonary disease and critical care medicine 219 programs, 2,445 fellows, 977 women (40.0%), 1,466 men (60.0%); internal medicine 688 programs, 34,086 residents, 15,730 women (46.1%). Sex in this book is self-reported and supplied by the AAMC, and the IP row counts fellows in training rather than the practicing physicians AABIP surveyed. https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf Corrected 2026-08-17: the demographics section put parent PCCM at ~33% of fellows and IM at ~40%, understating both by six to seven points, and cited them to 8, the AABIP compensation report, which carries no PCCM or IM gender figure. Understating the parent fields made IP's 17.8% read as closer to its parent than it is, so the section's own point about a male-skewed niche was weaker than the data supports. The section also treated the AABIP survey and parent-field figures as the only gender data available; ACGME publishes an IP row. ⟳ ↩

Researched with AI assistance and reviewed by hand. How this site is made